Physician profile
Alejandro E Gil
NPI 1417951963
$16,301.48
in general payments reported to CMS, 2019-2025
46 companies · $2,243 in 2025
The $2,243 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,589 · 2020: $2,048 · 2021: $1,964 · 2022: $1,820 · 2023: $2,793 · 2024: $2,844 · 2025: $2,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,873 · Travel and Lodging: $6.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,873.19 |
| Travel and Lodging | $6.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,566.13 | 2022-2025 | |
| Abbvie INC. | $1,186.96 | 2019-2025 | |
| Amgen INC. | $1,116.62 | 2023-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $1,066.71 | 2019-2022 | |
| Novo Nordisk INC | $975.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $949.33 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $906.20 | 2019-2022 | |
| Lilly USA, LLC | $880.20 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Allergan, INC. | $874.56 | 2019-2020 | |
| Pfizer INC. | $712.76 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $621.21 | 2021-2024 | Verquvo, Januvia |
| Sanofi-Aventis U.S. LLC | $601.59 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.68 | 2020-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $441.05 | 2023-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $361.77 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.